evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

493 questions · 506 findings · 45 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 137 · 27.1%GRADE not reported 26 · 5.1%Very low 101 · 20%Low 135 · 26.7%Moderate 78 · 15.4%High 29 · 5.7%

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Overall survival (OS) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with chemotherapy (low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Progression‐free survival · platinum‐sensitive recurrent EOC

It is very uncertain whether summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… changes progression‐free survival (PFS) compared with chemotherapy (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Overall survival (OS) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with placebo after chemotherapy (maintenance therapy) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Progression‐free survival · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… leads to lower progression‐free survival (PFS) compared with placebo after chemotherapy (maintenance therapy) (high certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… may leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with placebo after chemotherapy (maintenance therapy) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi… changes any severe adverse events (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (very low certainty).

1 finding from 1 review

Chemotherapy vs chemotherapy alone

Overall survival (taxane‐containing doublet therapy vs taxane monotherapy) · advanced gastric adenocarcinoma

Chemotherapy showed no clear difference in overall survival (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (low certainty).

1 finding from 1 review

Chemotherapy vs chemotherapy alone

Progression‐free survival (PSF) · advanced gastric adenocarcinoma

Chemotherapy showed no clear difference in progression‐free survival (non‐taxane monotherapy vs taxane… compared with chemotherapy (low certainty).

2 findings from 1 review

Chemotherapy vs chemotherapy alone

Tumour response rate (taxane‐containing doublet therapy vs taxane monotherapy) · advanced gastric adenocarcinoma

It is very uncertain whether chemotherapy changes tumour response rate (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (very low certainty).

1 finding from 1 review